v3.26.1
Segments - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
3 Months Ended
May 21, 2024
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting Information [Line Items]      
Stock-based compensation expense $ 600,000 $ 1,636,675 $ 1,692,267
Depreciation and amortization   81,402 85,261
Net loss   (13,460,895) (15,046,132)
Reportable Segment      
Segment Reporting Information [Line Items]      
Non-program expenses   1,469,553 1,204,385
Employee-related costs   6,067,936 5,378,938
Stock-based compensation expense   1,636,675 1,692,267
Depreciation and amortization   81,402 85,261
Other segment items   (1,874,139) (438,519)
Net loss   13,460,895 15,046,132
Reportable Segment | Atebimetinib (IMM-1-104)      
Segment Reporting Information [Line Items]      
Program expenses   4,055,258 4,257,936
Reportable Segment | Envometinib (IMM-6-415)      
Segment Reporting Information [Line Items]      
Program expenses   4,345 1,623,755
Reportable Segment | Other programs      
Segment Reporting Information [Line Items]      
Program expenses   $ 2,019,865 $ 1,242,109